Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Cancers|April 30, 2021
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell ActivationMélissa Prat, Marie Salon, Thibault Allain, et al.
The Journal of Clinical Investigation|July 28, 2007
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signalingChrystal M Paulos, Claudia Wrzesinski, Andrew Kaiser, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumorsRonan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Toll-like receptors in tumor immunotherapyChrystal M Paulos, Andrew Kaiser, Claudia Wrzesinski, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 15, 2020
Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's SyndromeElodie Rivière, Juliette Pascaud, Alexandre Virone, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer ConsortiumClaudia Pasqualini, Jonathan Rubino, Caroline Brard, et al.
Journal of Crohn'S & Colitis|October 3, 2017
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological EntitiesClélia Coutzac, Julien Adam, Emilie Soularue, et al.
Blood|March 21, 2008
Tumor-specific Th17-polarized cells eradicate large established melanomaPawel Muranski, Andrea Boni, Paul A Antony, et al.
Journal for Immunotherapy of Cancer|August 22, 2020
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanomaCeline Boutros, Nathalie Chaput-Gras, Emilie Lanoy, et al.
Journal for Immunotherapy of Cancer|July 27, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockersLaetitia Nebot-Bral, Antoine Hollebecque, Andrey A Yurchenko, et al.
Pageof 5